Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL993614 | 0.85 | MAOB (0.61) | MAOBMAPTPARP15PARP14PARP10 | |
| SCHEMBL15079868 | 0.84 | CYP1A2 (0.53) | MAOBTAAR1AOC3PARP15PARP14 | |
| SCHEMBL15079903 | 0.82 | MAOB (0.47) | MAOBTAAR1ALDH1A1MAPTSLC6A4 | |
| SCHEMBL5542124 | 0.81 | MAOB (0.46) | MAOBTAAR1AOC3PARP15PARP14 | |
| SCHEMBL20360954 | 0.79 | MAOB (0.47) | MAOBTAAR1PARP15PARP14PARP10 | |
| SCHEMBL15079383 | 0.79 | MAOB (0.51) | MAOBTAAR1ALDH1A1MAPTPARP15 | |
| SCHEMBL3714917 | 0.77 | MAOB (0.68) | MAOBMMP2 | |
| SCHEMBL15079380 | 0.77 | MAOB (0.56) | MAOBTAAR1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL993292 | 0.77 | MAOB (0.73) | MAOBTAAR1SIRT2 | |
| SCHEMBL5217402 | 0.76 | LMNA (0.43) | MAOBTAAR1ALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933065-B2 | N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140342989-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-20 | — | — | US | disclosed |
| US-8829033-B2 | N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2509939-A2 | NOVEL N-BENZYLAMIDE SUBSTITUED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACY-LAMIDO) PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS | The University of North Carolina At Chapel Hill (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120232015-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-09-13 | — | — | US | disclosed |
| WO-2011037833-A2 | NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACYLAMIDO)PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20110021482-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021482-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NAAA, AADAC, GBA1 | MAOB 394/4885TAAR1 1216/4885ALDH1A1 253/4885 |
| US-20140342989-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NAAA, AADAC, APEH | MAOB 312/4885TAAR1 1227/4885ALDH1A1 262/4885 |
| US-20120232015-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NAAA, AADAC, APEH | MAOB 327/4885TAAR1 1219/4885ALDH1A1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.